NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 96 filers reported holding NGM BIOPHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.75 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $36,475 | -86.8% | 34,089 | -49.7% | 0.00% | -100.0% |
| Q1 2023 | $276,595 | -60.4% | 67,793 | -51.2% | 0.00% | -50.0% |
| Q4 2022 | $697,860 | -28.9% | 139,016 | +85.4% | 0.00% | -33.3% |
| Q3 2022 | $981,000 | -58.0% | 74,998 | -58.8% | 0.01% | -57.1% |
| Q2 2022 | $2,333,000 | +88.4% | 181,986 | +124.2% | 0.01% | +40.0% |
| Q1 2022 | $1,238,000 | +15.2% | 81,170 | +33.7% | 0.01% | 0.0% |
| Q4 2021 | $1,075,000 | +30.1% | 60,706 | +54.5% | 0.01% | 0.0% |
| Q3 2021 | $826,000 | +101.0% | 39,284 | +88.7% | 0.01% | +100.0% |
| Q2 2021 | $411,000 | +10.8% | 20,820 | +63.3% | 0.01% | 0.0% |
| Q1 2021 | $371,000 | +539.7% | 12,751 | +560.7% | 0.01% | +400.0% |
| Q4 2020 | $58,000 | -58.3% | 1,930 | -77.9% | 0.00% | -50.0% |
| Q3 2020 | $139,000 | -59.2% | 8,748 | -49.3% | 0.00% | -66.7% |
| Q2 2020 | $341,000 | +2741.7% | 17,264 | +1612.7% | 0.01% | – |
| Q1 2020 | $12,000 | – | 1,008 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Column Group LLC | 15,396,116 | $303,611,000 | 42.97% |
| Ponoi II Management, LLC | 1,298,908 | $25,614,000 | 20.76% |
| Ponoi Management, LLC | 1,298,908 | $25,614,000 | 14.23% |
| Euclidean Capital LLC | 1,493,349 | $29,449,000 | 9.56% |
| RHO CAPITAL PARTNERS INC | 3,766,666 | $74,279,000 | 6.80% |
| Aquilo Capital Management, LLC | 1,194,237 | $23,550,000 | 6.12% |
| Greenspring Associates, LLC | 1,573,357 | $31,027,000 | 2.10% |
| Octagon Capital Advisors LP | 200,000 | $3,944,000 | 0.82% |
| Redmile Group, LLC | 2,792,448 | $55,067,000 | 0.82% |
| BVF INC/IL | 955,000 | $18,833,000 | 0.71% |